EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population‐Based Cohort Study

Itamar Ben Shitrit iD, Daphna Idan iD, Ariel Avraham Hasidim iD, Tal Michael iD, Amalia Levy iD, Gali Pariente iD, Eitan Lunenfeld iD, Sharon Daniel iD

Clinical Pharmacology & Therapeutics · 06.08.2026

DOI: 10.1002/cpt.70431 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.08.2026. Verfasst von Itamar Ben Shitrit und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Faculty of Health Sciences, University of the Nege…. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pain and fever are common in pregnancy. Dipyrone is widely used in Europe, Latin America, and parts of Asia, but is banned in other countries due to concerns about agranulocytosis. Evidence on its safety in pregnancy remains limited and inconsistent. This study aimed to evaluate whether maternal dipyrone use during the first‐ and third‐trimesters is associated with major congenital malformations (MCMs) and adverse perinatal or early neonatal outcomes. A population‐based cohort of all pregnancies that delivered or underwent elective termination at Soroka University Medical Center from 1998 to 2018, linking maternal, neonatal, and termination records with pharmacy dispensations. Generalized full matching and Poisson regression were used to study the association of first‐and third‐trimester dipyrone exposure and risks of MCMs, perinatal outcomes, and early neonatal complications, including preterm ductal closure and renal injury. Among 264,858 singleton pregnancies analyzed for first‐trimester exposure, 8,987 (3.4%) were exposed to Dipyrone. MCMs occurred in 8.0% of exposed vs. 7.0% of unexposed; however, no association was found after matching (adjusted risk ratio (RR) 1.04, 95% CI: 0.88–1.22). No associations were observed with malformation in other organ systems. In third‐trimester analyses ( n = 257,285; 6,362 (2.5%) exposed), dipyrone was not associated with preterm birth, low birthweight, perinatal death, low Apgar scores, or evidence of renal toxicity or premature ductus arteriosus constriction. No dose–response was observed. Sensitivity Analysis for over‐the‐counter use indicated minimal possible misclassification bias. This study provides evidence supporting maternal dipyrone use in early or late pregnancy is not associated with MCMs, adverse perinatal outcomes, or early neonatal complications.

Autor:innen und Institutionen

  • Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Faculty of Health Sciences, University of the Negev, Beer-Sheva, Israel.
  • Joyce and Irving Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Clinical Research Center, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Department of Pediatrics A, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Obstetrics and Gynecology, Faculty of Health Sciences Ben-Gurion University of the Negev and Soroka University Medical Center, Beer-Sheva, Israel.

ORCID-Profile: Itamar Ben Shitrit, Daphna Idan, Ariel Avraham Hasidim, Tal Michael, Amalia Levy, Gali Pariente, Eitan Lunenfeld, Sharon Daniel

Zitieren

APA

Shitrit, I. B., Idan, D., Hasidim, A. A., Michael, T., Levy, A., Pariente, G., Lunenfeld, E., & Daniel, S. (2026). Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population‐Based Cohort Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70431

Vancouver

Shitrit IB, Idan D, Hasidim AA, Michael T, Levy A, Pariente G, et al. Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population‐Based Cohort Study. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70431

BibTeX
@article{Shitrit2026,
  author = {Shitrit, Itamar Ben and Idan, Daphna and Hasidim, Ariel Avraham and Michael, Tal and Levy, Amalia and Pariente, Gali and Lunenfeld, Eitan and Daniel, Sharon},
  title = {Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population‐Based Cohort Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70431}
}
Kostenlos starten →